L-α-氨基-γ-胍基丁酸对美法仑治疗L1210小鼠白血病的影响。
Effect of L-alpha-amino-gamma-guanidinobutyric acid on melphalan therapy of the L1210 murine leukemia.
作者信息
Vistica D T, Rabon A, Rabinovitz M
出版信息
Cancer Lett. 1979 May;6(6):345-50. doi: 10.1016/s0304-3835(79)80092-0.
About half the mice administered a lethal inoculum of L1210 leukemia become 60-day survivors when treated with an appropriate dose of melphalan. Leucine completely abolishes this long-term survival by interfering with melphalan uptake into the tumor cells. L-alpha-Amino-gamma-guanidinobutyric acid, the lower homolog of arginine, promotes melphalan uptake in vitro only in the presence of leucine. When administered to mice with melphalan and a dose of leucine which negates the 50% cure rate of melphalan, it reduces the therapeutic interference of leucine. However, L-alpha-Amino-gamma-guanidinobutyric acid alone does not improve melphalan therapy, suggesting that endogenous leucine can play only a minor role in interference with therapy of the L1210 leukemia.
给半数接种致死剂量L1210白血病细胞的小鼠使用适当剂量的美法仑治疗后，约有一半小鼠能存活60天。亮氨酸通过干扰美法仑进入肿瘤细胞的过程，完全消除了这种长期存活现象。L-α-氨基-γ-胍基丁酸是精氨酸的低级同系物，仅在亮氨酸存在的情况下，能在体外促进美法仑的摄取。当将其与美法仑及一定剂量的亮氨酸一起给予小鼠时（该剂量的亮氨酸会使美法仑的治愈率降低50%），它能减少亮氨酸的治疗干扰。然而，单独使用L-α-氨基-γ-胍基丁酸并不能改善美法仑治疗效果，这表明内源性亮氨酸在干扰L1210白血病治疗中仅起次要作用。
Zotero 插件